KLAS: Decision support surveillance tools 'significantly' impact clinical outcomes

Clinical decision support surveillance tools have a moderate to significant impact on clinical outcomes for a majority of providers recently surveyed by Orem, Utah-based research firm KLAS.

In a report published this week, KLAS polled more than 140 providers about their use of CDS surveillance tools from 10 vendors. The vendors were divided into three categories: pharmacy-focused surveillance; enterprise-wide surveillance and electronic medical record surveillance.

Forty-eight percent said that the tools were "significant" to the outcomes of patients, while 31 percent said CDS surveillance had a "moderate" impact their patients. Five percent said the tools had no impact at all.

"Providers make it clear that they feel that CDS surveillance is having a positive impact on how well they are able to care for their patients," report author Adam Cherrington said in a statement.

Specifically, systems created by Epic, Hospira and Wolters Kluwer ranked high for their positive impact on patient outcomes. What's more, Epic and Siemens systems were praised by respondents for the ability to provide more actionable alerts.

Research recently published in JAMA Internal Medicine found that incorporating CDS predictive tools into electronic health record use could significantly decrease the use of antibiotics for respiratory tract infections.

Other studies have shown that CDS tools can improve patient care and reduce unnecessary tests, but that too many of them can have an adverse effect.

To learn more:
- purchase the report
- read the announcement